Caroline Palomeque
Stock Analyst at Maxim Group
(2.58)
# 2,175
Out of 4,876 analysts
9
Total ratings
55.56%
Success rate
16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Downgrades: Hold | n/a | $2.37 | - | 2 | Aug 14, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $31.98 | +84.49% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $138.88 | +10.89% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $52.21 | +11.09% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $172.14 | -3.57% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $14.10 | +176.60% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $8.39 | +627.06% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $9.48 | +321.94% | 1 | Jun 23, 2022 |
Daré Bioscience
Aug 14, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.37
Upside: -
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $31.98
Upside: +84.49%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $138.88
Upside: +10.89%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $52.21
Upside: +11.09%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $172.14
Upside: -3.57%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $14.10
Upside: +176.60%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $8.39
Upside: +627.06%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $9.48
Upside: +321.94%